Expertise in
3
conditions

Yuichiro Kikawa

Hirakata, JP 
Expertise in
3
conditions
Hirakata, JP 

Overview

Yuichiro Kikawa practices practicing medicine in Hirakata, Japan.

Kikawa is highly rated in 3 conditions, according to our data. Their clinical expertise encompasses Breast Cancer, Peripheral Neuropathy, Triple-Negative Breast Cancer, PIK3CA-Related Overgrowth Spectrum, and Mastectomy.

They are actively involved in clinical research, co-authoring 79 peer reviewed articles and participating in 2 clinical trials.

Locations

Hirakata, 5731191, Japan
Other Locations
Osaka, Japan
Kobe, Japan
Tokyo, Japan
Chuo, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy Plus Palbociclib Versus Hormonal Therapy Plus Placebo in Women With Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy Plus Palbociclib Versus Hormonal Therapy Plus Placebo in Women With Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
Enrollment Status: Completed
Publish Date: March 10, 2023
Intervention Type: Drug
Study Drugs: Palbociclib, Endocrine Therapy
Study Phase: Phase 3
Prospective Observational Study to Explore the Efficacy of Eribulin as 1st-line or 2nd-line Chemotherapy in Patients With HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer
Prospective Observational Study to Explore the Efficacy of Eribulin as 1st-line or 2nd-line Chemotherapy in Patients With HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: June 11, 2021
Intervention Type: Drug
View 1 Less Clinical Trial

79 Total Publications

SERENA-6 visual patient-reported outcomes & safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.
SERENA-6 visual patient-reported outcomes & safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.
Journal: The oncologist
Published: May 22, 2026

Frequently Asked Questions about Yuichiro Kikawa

Is Yuichiro Kikawa a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Yuichiro Kikawa is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Yuichiro Kikawa participate in research or clinical trials?

Yes. Yuichiro Kikawa has published 79 articles and abstracts on conditions like Breast Cancer. You can view a list of Yuichiro Kikawa's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Kikawa's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile